Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma

Therapeutics and Clinical Risk Management

Volumn 4, Issue 4, 2008, Pages 727-732

  Weide, Rudolf ^a  

^a Praxisklinik für Hämatologie und Onkologie ^*  (Germany)

Author keywords

Bendamustine; Non Hodgkin's lymphoma; Relapsed indolent

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; THROMBOCYTOPENIA; VOMITING;

EID: 53049109651     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Anger G, Hesse P, Köhler P, et al. 1967. Erste klinische Erfahrungen mit einem neuen Zytostatikum. Deutsch Gesundheitswes, 22:1079-84.
2. Anger G, Hesse P, Baufeld H. 1969. Behandlung des multiplen Myeloms mit einem neuen Zytostatikum. Dtsch Med Wochenschr, 48:2495-500.
3. Anger G, Fink R, Fleischer J, et al. 1975. Vergleichsuntersuchungen zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dern Bronchialkarzinom. Deutsch Gesundheitswes, 30:1280-5.
4. Armitage J. 1993. Treatment of non-Hodgkin's lymphoma. N Engl J Med, 328:1023-30.
5. Blumenstengel K, Fricke HJ, Kath R, et al. 1998. Bendamustine (B), vincristine (O), prednisone (P) in relapsed and refractory low grade non-Hodgkin's lymphoma (NHL) [abstract]. Ann Hematol, 77(Suppl 11):S149.
6. Bremer K. 2002. High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol, 128:603-9.
7. Brockmann B. 1992. Therapy of the recurrence of malignant lymphoma. Z Aerztl Fortbild (Jena), 86:843.
8. Chow KU, Boehrer S, Geduldig K, et al. 2001. In vitro studies of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica, 86:485-93.
9. Chow KU, Sommerlad WD, Boehrer S, et al. 2002. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica, 87:33-43.
10. Friedberg JW, Cohen P, Chen L, et al. 2008. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single agent study. J Clin Oncol, 26:204-10.
11. Haase D, Preiss R, Sohr R, et al. 1990. Untersuchungen zur Plasmaeiweißbindung von Bendamustin (Cytostasan) und Ambazone. Z Klin Med, 45:1267-71.
12. Hartmann M, Zimmer CH. 1972. Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943. Biochim Biophys Acta, 287:386-9.
13. Heck HK, Preiss JM, Schmidt P. 1998. Bendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin's lymphoma (NHL) [abstract]. J Cancer Res Clin Oncol, 124(Suppl):R147.
14. Heider A, Niederle N. 2001. Efficacy and toxicity of bendamustine in patients with relapsed low - grade non-Hodgkin's lymphomas. Anticancer Drugs, 12:725-9.
15. Herold M, Kemert K, Anger G, et al. 1992. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease - results of a pilot study. Onkologie, 15:501-5.
16. Herold M, Schulze A, Mantovani L, et al. 1999. BOP versus COP in advanced low-grade non-Hodgkin's lymphoma - results of a randomized multicenter trial [abstract]. Ann Oncol, 10(Suppl 3):125.
17. Herold M, Schulze A, Niederwieser D, et al. 2006. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol, 132:105-12.
18. Hesse G, Schulze W, Wachtel E. 1981. Zur Methodik der Bestimmung atkylierender Aktivitäten von N-Losten mit Nitrobezylpyridin (NBP) in biologischem Material. Pharmazie, 36:609-12.
19. Kahl C, Herold M, Höffkes H, et al. 1997. Bendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non-Hodgkin's lymphoma. Onkologie, 20:406-8.
20. Kahl B, Bartlett NL, Leonard JP, et al. 2007. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma [abstract]. Blood, 110:1351.
21. Kath R, H-desoffken K, Merkle K. 2000. Prevention of immunological complications in bendamustine treatment [abstract]. Onkologie, 23:171.
22. Kirchner HH, Gaede B, Steinhauer EU et al. 2001. Chemoimmunotherapy with Fludarabine, Bendamustine and Rituximab for relapsed low grade malignant non-Hodgkin's lymphoma [abstract]. Blood, 98:568.
23. König U, Junghass C, Decker S, et al. 1999. Response of refractory and relapsed low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride-containing regimen [abstract]. Ann Oncol, 10(Suppl 3):132.
24. Königsmann M, Knauf W, Herold M, et al. 2004. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - a multicenter phase I/II trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma, 45:1821-7.
25. Leoni LM, Bailey B, Reifert J, et al. 2008. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res, 14:309-17.
26. Matthias M, Preiss R, Sohr R et al. 1995. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract]. Proc Am Soc Clin Oncol, 14:1476.
27. Ozegowski W, Krebs D. 1963. w-[bis-(chlorethyl)-amino-benzimidazolyl- (2)]-propionic or butyric acids as potential cytostatic: agents. J Prakt Chem, 20:178-86.
28. Ozegowski W, Krebs D. 1971. IMET 3393, gamma-(1-methyl-5-bis-(β- chloräthyl)-aniino-benzimidazolyl(2)-buttersäure- hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol- Loste. Zbl Pharm, 110:1013-19.
29. Preiss R, Sohr R, Matthias M et al. 1985. The pharmacokinetics of bendamustine (Cytostasan) in humans. Pharmazie, 40:782-4.
30. Robinson KS, Williams ME, Cohen P, et al. 2005. Bendamustine HCl (TREANDA™) treatment in combination with rituximab results in objective responses inpatients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: Results from phase II multicenter study (SDX-105-02) [abstract]. Blood, 106:923.
31. Ruffert K, Jann H, Syrbe G, et al. 1989. Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin's lymphoma. Z Klin Med, 44:671-4.
32. Ruffert K. 1999. Therapy of low grade non-Hodgkin's lymphoma (NHL) with bendamustine and oral etoposide [abstract]. Ann Oncol, 10(Suppl 3):125.
33. Rummel MJ, Chow KU, Hölzer D, et al. 2002. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol, 29 (4 Suppl 13):12-14.
34. Rummel MJ, Al-Batran SE, Kim SZ, et al. 2005. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low - grade non Hodgkin's lymphoma. J Clin Oncol, 23:3383-9.
35. Rummel MJ, von Grünhagen U, Niederle N, et al. 2007. Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with indolent and mantle cell lymphomas - first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood, 110:385.
36. Schnabel R, Jungstand W, Gutsche W, et al. 1967. Comparative studies on the cystostatic activity of the new nitrogen mustard derivative IMET 3393 and endoxan in three experimental mouse tumours (Ehrlich-ascites-carcinoma, sarcoma 180 solid, leukaemia LAJ 1). Acta Biol Med, 19:534-58.
37. Schwänen C, Hecker T, Hübinger G, et al. 2002. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia, 16:2096-105.
38. Staib P, Schinkothe T, Dimiski T, et al. 1999. In vitro modulation of ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine [abstract]. Blood, 94:63.
39. Strumberg D, Harstrick A, Doll K, et al. 1996. Bendamustine hydrochloride activity against doxorubicine-resistant human breast cancer cell lines. Anticancer Drugs, 7:415-21.
40. Van der Jagt RH, Cohen P, Cheson BD, et al. 2006. Phase II Results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma [abstract]. Blood, 108:2710.
41. Weide R, Heymanns J, Köppler H. 1999. Successful treatment of alkylating agent resistant low grade B-cell non Hodgkin's lymphomas with bendamustine/mitoxantrone/rituximab (BMR) [abstract]. Onkologie, 22(Suppl 1):644.
42. Weide R, Heymanns J, Gores A, et al. 2002. Bendamustine, mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma, 43:327-31.
43. Weide R, Pandorf A, Heymanns J, et al. 2004. Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma, 45:2445-2449.
44. Weide R, Hess G, Köppler H, et al. 2007. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma, 48:1299-306.